Project Details
Description
A Phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also known as BAX 930/SHP655) in the prophylactic and on-demand treatment of subjects with severe con
| Status | Active |
|---|---|
| Effective start/end date | 3/4/22 → 3/31/27 |
Funding
- TAKEDA CAMBRIDGE LTD
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.